Point72 Asia (Singapore) Pte. Ltd. Myriad Genetics Inc Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $646 Billion
- Q3 2025
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Myriad Genetics Inc stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 7,324 shares of MYGN stock, worth $49,144. This represents 0.01% of its overall portfolio holdings.
Number of Shares
7,324
Previous 13,619
46.22%
Holding current value
$49,144
Previous $72.3 Million
26.78%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding MYGN
# of Institutions
239Shares Held
92.2MCall Options Held
86.1KPut Options Held
18.9K-
Black Rock Inc. New York, NY15.2MShares$102 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.88MShares$52.9 Million0.0% of portfolio
-
State Street Corp Boston, MA4.98MShares$33.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.75MShares$31.9 Million0.02% of portfolio
-
Glenview Capital Management, LLC New York, NY4.59MShares$30.8 Million0.75% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $541M
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...